AZN Stock Summary and Trading Ideas (Astrazeneca PLC | NYSE:AZN)

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Astrazeneca PLC trades on the NYSE stock market under the symbol AZN.

As of April 13, 2026, AZN stock price declined to $202.82 with 1,300,761 million shares trading.

AZN has a beta of 0.42, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.01 to the broad based SPY ETF.

AZN has a market cap of $314.43 billion. This is considered a Mega Cap stock.

Last quarter Astrazeneca PLC reported $16 billion in Revenue and $2.12 earnings per share. This fell short of revenue expectation by $-76 million and missed earnings estimates by -$.06.

In the last 3 years, AZN traded as high as $212.71 and as low as $60.47.

The top ETF exchange traded funds that AZN belongs to (by Net Assets): AVDE, PVAL, DIHP, DFIC, PPH.

AZN has outperformed the market in the last year with a return of +223.5%, while the SPY ETF gained +31.8%. In the last 3 month period, AZN beat the market returning +121.2%, while SPY returned -1.2%. However, in the most recent 2 weeks AZN has underperformed the stock market by returning +7.6%, while SPY returned +7.9%.

AZN support price is $200.39 and resistance is $207.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN shares will trade within this expected range on the day.